NASDAQ:ACOR Acorda Therapeutics (ACOR) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ACOR Stock Alerts $13.21 +1.30 (+10.91%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$11.82▼$13.3250-Day Range$11.91▼$17.0552-Week Range$8.98▼$24.20Volume4,531 shsAverage Volume4,527 shsMarket Capitalization$16.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Acorda Therapeutics alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Acorda Therapeutics Stock (NASDAQ:ACOR)Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Read More ACOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACOR Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comAcorda Therapeutics (NASDAQ:ACOR) Now Covered by Analysts at StockNews.comMarch 26, 2024 | finance.yahoo.comAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 19, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Acorda Therapeutics (NASDAQ:ACOR)March 11, 2024 | finance.yahoo.comKlick Health Launches First AI Social Media Comment Moderator for Life Sciences IndustryFebruary 28, 2024 | stocknews.com3 Biotech Stocks to Watch in March for SuccessFebruary 23, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR), Short Interest ReportFebruary 22, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR) Dividends: History, Yield and DatesMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 20, 2024 | msn.comAcorda: No policy vs. TikTok use in PNPFebruary 6, 2024 | msn.comAcorda: PNP can’t interfere with people’s initiative for Charter changeFebruary 5, 2024 | msn.comTeodoro, Acorda nix Mindanao separation from PhilippinesJanuary 31, 2024 | msn.comPNP chief Acorda tells ranks: Ignore ‘political noise’January 29, 2024 | finance.yahoo.comDementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis - TechnavioJanuary 11, 2024 | markets.businessinsider.comAcorda Therapeutics To Regain Worldwide Commercialization Rights To FAMPYRAJanuary 10, 2024 | stocknews.com3 Biotech Stocks to Keep an Eye on in 2024January 8, 2024 | msn.comAcorda files raps vs person spreading false info in viral vlogJanuary 8, 2024 | msn.comAcorda slams vlogger in 'disinformation' driveJanuary 8, 2024 | msn.comAcorda files cybercrime raps vs person spreading false info in a vlogJanuary 7, 2024 | msn.comAcorda eyes Pinoy apps vs cybercrimesJanuary 6, 2024 | morningstar.comAcorda Therapeutics Inc ACORJanuary 4, 2024 | finance.yahoo.comAshvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical OperationsDecember 18, 2023 | stocknews.comModerna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?December 18, 2023 | finance.yahoo.comAcorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The IndustryDecember 15, 2023 | stocknews.com3 Biotech Stocks Flashing Year-End 'Buy' Signals"November 24, 2023 | stocknews.com3 Safe Biotech Stocks to Buy This WeekNovember 14, 2023 | finance.yahoo.comAcorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call TranscriptSee More Headlines Receive ACOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Confirmed)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:ACOR CUSIP00484M10 CIK1008848 Webwww.acorda.com Phone(914) 347-4300Fax914-347-4560Employees111Year Founded1995Profitability EPS (Most Recent Fiscal Year)($17.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,920,000.00 Net Margins-14.35% Pretax Margin-16.72% Return on Equity-21.45% Return on Assets-4.25% Debt Debt-to-Equity Ratio3.07 Current Ratio1.59 Quick Ratio1.21 Sales & Book Value Annual Sales$118.57 million Price / Sales0.14 Cash FlowN/A Price / Cash FlowN/A Book Value$77.13 per share Price / Book0.17Miscellaneous Outstanding Shares1,240,000Free Float1,210,000Market Cap$16.38 million OptionableNo Data Beta1.41 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Ron Cohen M.D. (Age 68)Founder, CEO, President & Director Comp: $984.15kMr. Michael A. Gesser M.B.A. (Age 61)Chief Financial Officer Comp: $459.15kMr. Kerry M. Clem (Age 54)Chief Commercial Officer Comp: $592.23kMr. Robert Morales (Age 56)Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller Ms. Felicia VonellaVice President of Investor RelationsMr. Neil S. Belloff Esq. (Age 64)General Counsel & Corporate Secretary Ms. Tierney SaccavinoExecutive Vice President of Corporate CommunicationsMs. Denise J. DucaExecutive Vice President of Human ResourcesMr. Andrew Mayer J.D.Senior Vice PresidentSofia AliSenior VP of Operations & Strategic PlanningMore ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSInhibikase TherapeuticsNYSE:IKTEvaxion Biotech A/SNASDAQ:EVAXSenti BiosciencesNASDAQ:SNTIBioCardiaNASDAQ:BCDAView All Competitors ACOR Stock Analysis - Frequently Asked Questions How have ACOR shares performed in 2024? Acorda Therapeutics' stock was trading at $15.09 at the start of the year. Since then, ACOR shares have decreased by 12.5% and is now trading at $13.2110. View the best growth stocks for 2024 here. Are investors shorting Acorda Therapeutics? Acorda Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 9,500 shares, a decline of 14.4% from the February 29th total of 11,100 shares. Based on an average daily trading volume, of 3,800 shares, the short-interest ratio is currently 2.5 days. Currently, 0.8% of the company's shares are short sold. View Acorda Therapeutics' Short Interest. When is Acorda Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our ACOR earnings forecast. How can I listen to Acorda Therapeutics' earnings call? Acorda Therapeutics will be holding an earnings conference call on Monday, April 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "732092". How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) EPS for the quarter, topping analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company earned $31.46 million during the quarter, compared to analyst estimates of $30.57 million. Acorda Therapeutics had a negative net margin of 14.35% and a negative trailing twelve-month return on equity of 21.45%. When did Acorda Therapeutics' stock split? Acorda Therapeutics shares reverse split on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Ron Cohen's approval rating as Acorda Therapeutics' CEO? 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT). Who are Acorda Therapeutics' major shareholders? Acorda Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Acorda Therapeutics? Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACOR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.